Pharma Journalist -

Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for LORVIQUA (lorlatinib, approved…
Read More...

Novartis announced new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The…
Read More...

Pacira Pharmaceuticals and MyoScience announced the signing of a definitive agreement for the acquisition of MyoScience by Pacira. MyoScience currently markets the ioveraº system, a…
Read More...

ReForm Biologics announced a collaboration with Astellas Pharma Inc. to reduce the viscosity of an Astellas clinical-stage biological pipeline program. Reform’s technology platform…
Read More...

Bayer has submitted an application for marketing authorization to the Ministry of Health, Labor and Welfare (MHLW) in Japan for darolutamide for the treatment of patients with…
Read More...

AnTolRx announced that Pfizer Inc. has exercised the option granted under a June 2016 agreement to license an immune tolerance therapy from AnTolRx's Type 1 diabetes research program.…
Read More...

SMi reports: The 21st annual Superbugs & Superdrugs conference will be returning to London in just two weeks’ time. As the frequency of antibiotic resistance experiences a steady…
Read More...

The countdown begins to the highly anticipated Adaptive Designs in Clinical Trials conference in April this year. With the growing popularity in use and acceptance of adaptive…
Read More...

Nichi-Iko Pharmaceutical Co., Ltd. and Sagent Pharmaceuticals, Inc., a Nichi-Iko Group Company announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North…
Read More...

Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the…
Read More...